Skip to main content
. 2017 Jan 31;8(29):46915–46927. doi: 10.18632/oncotarget.14911

Figure 7. Concomittant application of Vandetanib, GDC-0941 and Etoposide displays additive cytotoxic activity.

Figure 7

Daoy, MEB-Med-8A, D283 Med and D341 Med were treated with increasing concentrations of the standard chemotherapeutic Etoposide (0.1, 0.5, 1, 5, 10 μM) in combination with 2 μM of Vandetanib and 1 μM of GDC-0941. 1-2 μM of Etoposide corresponds to cerebral spinal fluid levels, while 10 μM of Etoposide corresponds to plasma levels. The vehicle DMSO served as control. After 48 h drug exposure cell viability was assessed by means of the MTS assay. Each experiment was performed in triplicates and repeated four times.